

ForPatients

by Roche

Diabetic Macular Edema

A Study to Investigate RO7200220 in Combination With Ranibizumab in Diabetic Macular Edema

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Trial Status
Completed

Trial Runs In
9 Countries

Trial Identifier
NCT05151744 2021-004390-31
BP43464

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT05151744 2021-004390-31 BP43464
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
